KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Accumulated Depreciation (2017 - 2021)

Historic Accumulated Depreciation for Aquestive Therapeutics (AQST) over the last 5 years, with Q1 2021 value amounting to $37.8 million.

  • Aquestive Therapeutics' Accumulated Depreciation fell 238.92% to $37.8 million in Q1 2021 from the same period last year, while for Mar 2021 it was $37.8 million, marking a year-over-year decrease of 238.92%. This contributed to the annual value of $40.9 million for FY2020, which is 744.93% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Accumulated Depreciation of $37.8 million as of Q1 2021, which was down 238.92% from $40.9 million recorded in Q4 2020.
  • Aquestive Therapeutics' 5-year Accumulated Depreciation high stood at $40.9 million for Q4 2020, and its period low was $32.0 million during Q4 2017.
  • Moreover, its 5-year median value for Accumulated Depreciation was $37.3 million (2019), whereas its average is $37.0 million.
  • In the last 5 years, Aquestive Therapeutics' Accumulated Depreciation surged by 995.47% in 2018 and then crashed by 238.92% in 2021.
  • Over the past 5 years, Aquestive Therapeutics' Accumulated Depreciation (Quarter) stood at $32.0 million in 2017, then increased by 9.95% to $35.2 million in 2018, then increased by 8.11% to $38.0 million in 2019, then rose by 7.45% to $40.9 million in 2020, then decreased by 7.45% to $37.8 million in 2021.
  • Its Accumulated Depreciation was $37.8 million in Q1 2021, compared to $40.9 million in Q4 2020 and $40.2 million in Q3 2020.